Teva Pharmaceutical Industries Ltd.
Tel Aviv: TEVA
——
Tel Aviv share prices are coming to this site soon. The chart below is its listing abroad.
NYSE: TEVA
——
The chart fills in as daily closes arrive.
52-week range — – —
End-of-day prices. Not live quotes, and not investment advice.
Funding and exits
No funding round or acquisition of Teva Pharmaceutical Industries Ltd. has been reported on this site yet.
Teva Pharmaceutical Industries Ltd. in the news

Surprise Departure: Teva's Chief Medical Officer Receives Alternative Offer and Leaves Immediately
Dr. Arik Yoez, who served as Teva's Chief Medical Officer for the past four years, has departed the company to accept another offer. CEO Richard Francis stated that Yoez is leaving Teva in a strong position for the next chapter.
Globes (Hebrew, translated) · 2 days ago · Teva Pharmaceutical Industries Ltd.

Teva to join Russell 1000 large-cap index
Teva Pharmaceutical will be included in the Russell 1000 index of large-cap US companies.
Globes · 3 days ago · Teva Pharmaceutical Industries Ltd.

Teva CEO: We have evolved into a biopharma company
Teva CEO Richard Francis stated that the company is evolving into a biopharma company, with branded drugs expected to account for 25% of revenue by 2030, up from 9% in 2022.
Globes · 1 week ago · Teva Pharmaceutical Industries Ltd.

Teva CEO: 'The future looks especially promising; we are also looking at larger acquisitions'
Teva is raising its revenue target from innovative medicines to $6-7 billion by 2030 and shows growth in cash flow and product pipeline. The CEO Richard Francis said the company is looking at larger acquisitions despite past challenges.
Globes (Hebrew, translated) · 1 week ago · Teva Pharmaceutical Industries Ltd.

Teva again raises guidance as branded drugs lift revenue
Teva reported third-quarter revenue of $4.4 billion, beating analyst expectations of $4.2 billion, and non-GAAP earnings per share of $0.86, exceeding the consensus of $0.72.
Globes · 2 weeks ago · Teva Pharmaceutical Industries Ltd.

Teva's flagship drugs deliver positive quarter and improved revenue guidance
Teva Pharmaceutical reported revenues of $4.4 billion, beating analyst expectations on both top and bottom lines, and raised its full-year 2026 guidance.
Globes (Hebrew, translated) · 2 weeks ago · Teva Pharmaceutical Industries Ltd.

Five Things to Know Before the Stock Exchange Opens
The Tel Aviv Stock Exchange opens a new week amid global uncertainty, with earnings season arriving in Israel featuring reports from Tower, Teva, and Kamtec, while major U.S. stocks like Apple and Palantir report earnings and mid-term elections approach.
Globes (Hebrew, translated) · 2 weeks ago · Tower Semiconductor Ltd., Teva Pharmaceutical Industries Ltd., Kamtec

What will dual-listed stocks do tomorrow, and is a new shock coming to Wall Street?
U.S. midterm elections may disrupt Wall Street, while markets begin pricing in a possible return to war against Iran. Tel Aviv and New York bourses closed a red month, with money flowing out of technology stocks into defensive sectors.
Globes (Hebrew, translated) · 2 weeks ago · Tower Semiconductor Ltd., Teva Pharmaceutical Industries Ltd., El Al Israel Airlines Ltd.

Five things to know before the stock exchange opens for trading
The Tel Aviv Stock Exchange reopens after a difficult week. Teva will surge following FDA approval for a schizophrenia drug, while Alko will transfer 95 million shekels to Electra Real Estate.
Globes (Hebrew, translated) · 1 month ago · Teva Pharmaceutical Industries Ltd., Alko, Electra Real Estate Ltd.

Over 5x jump since the low: Teva's comeback
A decade after the crisis that removed Teva from its status as Israel's flagship stock, the pharmaceutical giant has completed a comeback. The company's market value in New York has reached $47.9 billion, making it again the highest-valued Israeli company on the local exchange.
Globes (Hebrew, translated) · 1 month ago · Teva Pharmaceutical Industries Ltd.

FDA Approval for Teva's Once-Monthly Schizophrenia Injection Weltruza Boosts Share Price
Teva announced FDA approval for Weltruza, a once-monthly injection for schizophrenia treatment, reaching a share price level not seen in a decade.
Globes · 1 month ago · Teva Pharmaceutical Industries Ltd.

Israeli company soared to a decade high and another lost ground
Teva's stock jumped to its highest price since 2016 following approval for a new schizophrenia drug. Citi Bank downgraded Nova, which has fallen over 40% from its June peak.
Globes (Hebrew, translated) · 1 month ago · Teva Pharmaceutical Industries Ltd., Similarweb Ltd., Nova
More in Pharma & biotech
| Company | Industry | Listed | Close | Day | Market value |
|---|---|---|---|---|---|
| BioHarvest Sciences Inc. | Pharma & biotech | Tel Aviv: BHST | — | — | — |
| Biolight Life Sciences Ltd. | Pharma & biotech | Tel Aviv: BOLT | — | — | — |
| BioLineRx Ltd. | Pharma & biotech | Tel Aviv: BLRX | — | — | — |
| Bio View Ltd. | Pharma & biotech | Tel Aviv: BIOV | — | — | — |
| Bonus BioGroup Ltd. | Pharma & biotech | Tel Aviv: BONS | — | — | — |
| Can-Fite BioPharma Ltd. | Pharma & biotech | Tel Aviv: CANF | — | — | — |

